Interleukin-32 as a biomarker in rheumatic diseases: A narrative review
Interleukin-32 (IL-32) is an important cytokine involved in the innate and adaptive immune responses. The role of IL-32 has been studied in the context of various diseases. A growing body of research has investigated the role of IL-32 in rheumatic diseases including inflammatory arthritides (rheumat...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1140373/full |
| _version_ | 1797924625667063808 |
|---|---|
| author | Oh Chan Kwon Min-Chan Park Yong-Gil Kim Yong-Gil Kim |
| author_facet | Oh Chan Kwon Min-Chan Park Yong-Gil Kim Yong-Gil Kim |
| author_sort | Oh Chan Kwon |
| collection | DOAJ |
| description | Interleukin-32 (IL-32) is an important cytokine involved in the innate and adaptive immune responses. The role of IL-32 has been studied in the context of various diseases. A growing body of research has investigated the role of IL-32 in rheumatic diseases including inflammatory arthritides (rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis) and connective tissue diseases (systemic lupus erythematosus, systemic sclerosis, granulomatosis and polyangiitis, and giant cell arteritis). IL-32 has been shown to play different roles according to the type of rheumatic diseases. Hence, the putative role of IL-32 as a biomarker is also different in each rheumatic disease: IL-32 could serve as a biomarker for disease activity in some diseases, whereas in other diseases it could be a biomarker for certain disease manifestations. In this narrative review, we summarize the associations between IL-32 and various rheumatic diseases and discuss the putative role of IL-32 as a biomarker in each disease. |
| first_indexed | 2024-04-10T15:03:51Z |
| format | Article |
| id | doaj.art-1a9bbfc55f10449c8337dd866528e2e6 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T15:03:51Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-1a9bbfc55f10449c8337dd866528e2e62023-02-15T06:22:14ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-02-011410.3389/fimmu.2023.11403731140373Interleukin-32 as a biomarker in rheumatic diseases: A narrative reviewOh Chan Kwon0Min-Chan Park1Yong-Gil Kim2Yong-Gil Kim3Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of KoreaDivision of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of KoreaDivision of Rheumatology, Department of Internal Medicine, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Republic of KoreaConvergence Medicine Research Center, Asan Institution for Life Science, Asan Medical Center, Seoul, Republic of KoreaInterleukin-32 (IL-32) is an important cytokine involved in the innate and adaptive immune responses. The role of IL-32 has been studied in the context of various diseases. A growing body of research has investigated the role of IL-32 in rheumatic diseases including inflammatory arthritides (rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis) and connective tissue diseases (systemic lupus erythematosus, systemic sclerosis, granulomatosis and polyangiitis, and giant cell arteritis). IL-32 has been shown to play different roles according to the type of rheumatic diseases. Hence, the putative role of IL-32 as a biomarker is also different in each rheumatic disease: IL-32 could serve as a biomarker for disease activity in some diseases, whereas in other diseases it could be a biomarker for certain disease manifestations. In this narrative review, we summarize the associations between IL-32 and various rheumatic diseases and discuss the putative role of IL-32 as a biomarker in each disease.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1140373/fullIL-32biomarkerrheumatic diseaseinflammatory arthritisconnective tissue disease |
| spellingShingle | Oh Chan Kwon Min-Chan Park Yong-Gil Kim Yong-Gil Kim Interleukin-32 as a biomarker in rheumatic diseases: A narrative review Frontiers in Immunology IL-32 biomarker rheumatic disease inflammatory arthritis connective tissue disease |
| title | Interleukin-32 as a biomarker in rheumatic diseases: A narrative review |
| title_full | Interleukin-32 as a biomarker in rheumatic diseases: A narrative review |
| title_fullStr | Interleukin-32 as a biomarker in rheumatic diseases: A narrative review |
| title_full_unstemmed | Interleukin-32 as a biomarker in rheumatic diseases: A narrative review |
| title_short | Interleukin-32 as a biomarker in rheumatic diseases: A narrative review |
| title_sort | interleukin 32 as a biomarker in rheumatic diseases a narrative review |
| topic | IL-32 biomarker rheumatic disease inflammatory arthritis connective tissue disease |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1140373/full |
| work_keys_str_mv | AT ohchankwon interleukin32asabiomarkerinrheumaticdiseasesanarrativereview AT minchanpark interleukin32asabiomarkerinrheumaticdiseasesanarrativereview AT yonggilkim interleukin32asabiomarkerinrheumaticdiseasesanarrativereview AT yonggilkim interleukin32asabiomarkerinrheumaticdiseasesanarrativereview |